An Introduction to Multiple Myeloma
Despite numerous advances in the last decade, multiple myeloma remains an incurable disease, characterised by relapses that ultimately result in uncontrolled disease and death. However, novel agents, such as proteasome inhibitors, immunomodulatory drugs and CD38-directed monoclonal antibodies, have substantially improved survival and tolerability. These emerging agents include immune checkpoint inhibitors and chimeric antigen receptor-engineered T-cell therapies, although eventual relapse remains an issue.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Multiple Myeloma Content
Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma
Oncology & Hematology Review (US). 2020; 16(1):12–4 DOI: https://doi.org/10.17925/OHR.2020.16.1.12
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma.1 Although recent decades have seen considerable advances and improvements in clinical outcomes for patients with MM,2 MM remains incurable, with a high disease burden.3 Clonal evolution and genomic instability within myeloma clones inevitably lead to disease progression and treatment resistance.4 An increasing number […]
Current management of relapsed/refractory multiple myeloma and the future integration of BCMA-targeting agents
Watch a panel of internationally renowned multiple myeloma experts discuss the management of relapsed/refractory disease and the future for B-cell maturation antigen (BCMA)-targeted agents
- Discuss how treatment for patients with relapsed/refractory multiple myeloma can be selected based on disease- and patient-related factors
- Describe the rationale for B-cell maturation antigen (BCMA) as a treatment target and current agents in development
- Recall the latest data for BCMA-targeting agents in relapsed/refractory multiple myeloma and consider how they may be incorporated into clinical practice
BMCA-targeting agents in relapsed/refractory multiple myeloma: Distilling the data from the ASCO Annual Meeting 2020
Find out about the latest data on the use of B-cell maturation antigen (BCMA)-targeted therapies in the management of relapsed/refractory multiple myeloma through our touchCONGRESS Webinar and Expert Interviews with European experts discussing data from ASCO20 Virtual.
- Discuss the need for new treatment options for relapsed/refractory multiple myeloma and the rationale for targeting B-cell maturation antigen (BCMA)
- Describe the latest efficacy data for BCMA-targeting agents and evaluate how they may be integrated into the current treatment pathway
- Describe the latest safety data for BCMA-targeting agents and consider how adverse events could be managed in clinical practice
Biomarkers and novel therapies in relapsed/refractory multiple myeloma: Where are we heading in 2020?
Watch leading expert Prof. Graham Jackson discuss the importance of identifying high-risk patients with relapsed/refractory multiple myeloma and the role of biomarkers and novel therapies in optimizing individual patient care.
- Identify those patients with relapsed/refractory multiple myeloma with the most significant unmet needs
- Describe existing and novel biomarker testing and the relevance for optimizing the treatment of relapsed/refractory multiple myeloma
- Discuss the evidence for novel treatments and the potential for further treatment optimization with combination treatments in clinical trials and practice
Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma
We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]
A Patient Presenting with Severe Hypoglycaemia and Autonomic Instability Found to Have Multiple Myeloma Complicated with Amyloidosis
European Oncology & Haematology. 2019;15(2):106–8
Amyloidosis is a group of diseases resulting from intracellular and extracellular deposition of insoluble abnormal amyloid fibrils, which alters the normal function of tissues. Glycosaminoglycans, apolipoprotein-E and serum amyloid P component comprise 10% of deposits, while amyloid fibrils formed by misfolded proteins comprise 90% of deposits. Amyloidosis can locally target a single organ or can […]
Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma
Oncology & Hematology Review (US). 2019;15(2):87–90
An ever-expanding understanding of the biological basis for multiple myeloma (MM) combined with a widening array of effective therapies has dramatically improved outcomes for patients and has provided new opportunities for disease segmentation and targeted therapeutics.1 While this progress is most welcome, it has created unique challenges for clinicians because of the spatial and temporal heterogeneity, […]
Louis Williams, ASH 2019: Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma
At the 61st ASH Annual Meeting & Exposition, Louis Williams, NYU Langone Medical Center, provides a snapshot of his recent article with Oncology & Hematology (US) exploring genetic segmentation and targeted therapeutics for multiple myeloma. Questions 1. How has increased understanding of the molecular biology of multiple myeloma impacted on risk stratification of patients? (0:05) […]
Shaji Kumar, ASH 2019: Advances in treatment approaches and guidelines for multiple myeloma
At the 61st ASH Annual Meeting & Exposition, Editor-in-Chief of Oncology & Hematology Review (US) Shaji Kumar (Mayo Clinic) discusses the latest advances in the treatment and guidelines of multiple myeloma. Questions 1. What have been the most exciting recent development in the treatment of multiple myeloma? (0:05) 2. According to the most recent guidelines, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!